Who Paid My Doc
A Phase 1/2, Randomized, Dose-Finding/Dose-Confirmation Study to Evalu
Research payments
$3,137,741
Through program year 2024, $3,137,741 in research payments was reported against A Phase 1/2, Randomized, Dose-Finding/Dose-Confirmation Study to Evalu, across 135 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $397,967 | 26 |
| 2023 | Research | $2,739,774 | 109 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- William Seger Fort Worth, TX Named on 18 payments
- Vicki Miller Houston, TX Named on 13 payments
- Kimberly Cruz Miami, FL Named on 11 payments
- Mark Adams Lexington, KY Named on 9 payments
- George Freeman Newport News, VA Named on 9 payments
- William Smith New Orleans, LA Named on 8 payments
- Rupal Trivedi Chicago, IL Named on 7 payments
- David Fried East Greenwich, RI Named on 6 payments
- Carlos Fierro Lenexa, KS Named on 6 payments
- Terry Klein Wichita, KS Named on 5 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.